Post Thumbnail

Strong scientific presence of TRB at WCO IOF-ESCEO virtual congress 2020

TRB is pleased to support the first 100% virtual WCO-IOF-ESCEO e-congress which will take place from August 20 to 22 and available online until November 20, 2020. We are waiting for your visit at our booth in the virtual exhibition area!

TRB is also proud to host a Satellite Symposium entitled “Hyaluronic acid efficacy in osteoarthritis: beyond standard clinical parameters” which will be available online until November 20, 2020. This Symposium, chaired by Prof. Jean-Yves Reginster, University of Liège, will focus on the use of additional endpoints in clinical trials evaluating the efficacy of intra-articular hyaluronic acid such as our Ostenil products in osteoarthritis.

In addition, two posters summarising post-hoc analyses of TRB-sponsored clinical trials will be presented during the congress. Dr. Maheu, APHP Hôpital St-Antoine, Paris, will present the results of a post-hoc analysis of OSTP-EUR-10-01, a study published last December in PLoS One. This analysis compares the various definitions of responders that can be used in osteoarthritis (PASS, OMERACT-OARSI, MCII) and aimed at identifying predictive factors of a better response following intra-articular injection of hyaluronic acid.

The second poster is focusing on diacerein, a symptomatic slow-acting drug for osteoarthritis (SYSADOA). Prof. Jean-Pierre Pelletier, University of Montréal Hospital Research Centre, will discuss a post-hoc analysis of the DISSCO trial (A multicentre study on the effect of DIacerein on Structure and Symptoms versus Celecoxib in Osteoarthritis) aimed at exploring the influence of patient age on the magnitude of response to treatment with diacerein. Data revealed no differences between the efficacy and safety profile of diacerein in knee osteoarthritis patients younger or older than 65 years of age.

We are looking forward to participating in the first virtual WCO-IOF-ESCEO congress and hope that you share our excitement!

Visit the virtual congress

Post Thumbnail

31st annual French Rheumatology Society Congress, 9-11 December 2018, Paris (past event)

 

TRB Chemedica International will be present at the 31st congress of the French Rheumatology Society (Société Française de Rhumatologie) to be held at the Porte de Versailles Exhibition Center, Paris.

Learn more

Post Thumbnail

6th World Congress on Bone, Muscle & Joint Diseases (BMJD), 8-10 November 2018, Bangkok (past event)

TRB Chemedica will be present at the BMJD congress in Bangkok as Gold Sponsor. We are looking forward to meeting you during our symposium.

LUNCH SYMPOSIUM

NEW PERSPECTIVES WITH DIACEREIN
Friday November 9, 2018 Hall A 11:55 − 12:45

CHAIRPERSON
Pongsak Yuktanandana, Thailand

SPEAKERS
Johanne Martel-Pelletier, Canada
Jean-Pierre Pelletier, Canada
Worawit Louthrenoo, Thailand

Program
Preclinical evidence supporting the therapeutic effect of
Diacerein in osteoarthritis

Johanne Martel-Pelletier, Canada
An international, multicentre, double-blind, randomised
study of the effect of Diacerein vs. Celecoxib in
symptomatic knee osteoarthritis patients (DISSCO study)

Jean-Pierre Pelletier, Canada
Diacerein as an adjunct to methotrexate in the treatment of
rheumatoid arthritis: Results of a multicentre, double-blind,
randomized, placebo-controlled trial

Worawit Louthrenoo, Thailand
Q&A/Discussion

Learn more

Post Thumbnail

Exporter demain! Growing internationally between globalization and protectionism (past event)

In collaboration with BioAlps, Alessandro di Napoli VP of TRB Chemedica International will share is experience at the largest annual meeting of West Switzerland’s export economy: EXPORTER DEMAIN! 2018.

Learn more

Post Thumbnail

TRB Chemedica will be present at the CPHI in Madrid (past event)

Visit us during the CPHI Worldwide in Madrid. We will be present at the stand 14.1D70 – Hall 14.1.

Learn more

You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.

As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.

CONTINUE